Neoleukin Therapeutics (NLTX) Competitors $15.33 -1.90 (-11.03%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends NLTX vs. XBIT, FLXN, VECT, ANNX, HUMA, CRVS, ABVX, ATXS, IGMS, and GLUEShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include XBiotech (XBIT), Flexion Therapeutics (FLXN), VectivBio (VECT), Annexon (ANNX), Humacyte (HUMA), Corvus Pharmaceuticals (CRVS), ABIVAX Société Anonyme (ABVX), Astria Therapeutics (ATXS), IGM Biosciences (IGMS), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "medical" sector. Neoleukin Therapeutics vs. XBiotech Flexion Therapeutics VectivBio Annexon Humacyte Corvus Pharmaceuticals ABIVAX Société Anonyme Astria Therapeutics IGM Biosciences Monte Rosa Therapeutics Neoleukin Therapeutics (NASDAQ:NLTX) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Does the media favor NLTX or XBIT? In the previous week, XBiotech had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for Neoleukin Therapeutics. XBiotech's average media sentiment score of 1.11 beat Neoleukin Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral XBiotech Positive Does the MarketBeat Community prefer NLTX or XBIT? XBiotech received 267 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% XBiotechOutperform Votes31769.98% Underperform Votes13630.02% Which has more risk and volatility, NLTX or XBIT? Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Do institutionals and insiders hold more shares of NLTX or XBIT? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 33.1% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings & valuation, NLTX or XBIT? XBiotech has higher revenue and earnings than Neoleukin Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-4.93XBiotech$4.01M49.63-$24.56M-$1.08-6.05 Is NLTX or XBIT more profitable? XBiotech's return on equity of -15.99% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% XBiotech N/A -15.99%-14.85% SummaryXBiotech beats Neoleukin Therapeutics on 12 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.07M$6.50B$5.09B$8.81BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-4.935.4594.6014.18Price / SalesN/A373.721,217.5288.10Price / CashN/A52.5939.4936.27Price / Book1.3810.266.956.35Net Income-$57.56M$153.22M$118.83M$225.71M7 Day Performance-60.89%-1.74%-1.52%-0.32%1 Month Performance-70.89%-7.22%-3.39%1.76%1 Year Performance18.29%31.69%32.17%27.70% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeXBITXBiotech0.8966 of 5 stars$6.53+0.6%N/A+77.8%$199.03M$4.01M-6.01100Positive NewsFLXNFlexion TherapeuticsN/A$9.12flatN/AN/A$458.93M$85.55M-4.54257Analyst ForecastVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeANNXAnnexon2.7832 of 5 stars$5.35+3.7%$15.80+195.3%+100.0%$570.26MN/A-5.1060Analyst RevisionHUMAHumacyte2.8902 of 5 stars$4.51+2.3%$11.00+143.9%+71.6%$567.63M$1.57M0.00150Insider TradeNews CoverageCRVSCorvus Pharmaceuticals2.7832 of 5 stars$8.79+6.7%$12.83+46.0%+449.3%$564.85MN/A-8.8630Analyst RevisionABVXABIVAX Société Anonyme3.0118 of 5 stars$8.75-1.2%$39.80+354.9%-19.6%$553.79MN/A0.0061ATXSAstria Therapeutics1.7093 of 5 stars$9.72+1.5%$25.60+163.4%+110.5%$548.50MN/A0.0030Analyst RevisionIGMSIGM Biosciences4.7096 of 5 stars$9.07-7.2%$16.13+77.8%+63.3%$539.30M$2.13M-2.47190GLUEMonte Rosa Therapeutics2.9694 of 5 stars$8.77+4.9%$16.00+82.4%+157.2%$538.83MN/A0.0090 Related Companies and Tools Related Companies XBiotech Alternatives Flexion Therapeutics Alternatives VectivBio Alternatives Annexon Alternatives Humacyte Alternatives Corvus Pharmaceuticals Alternatives ABIVAX Société Anonyme Alternatives Astria Therapeutics Alternatives IGM Biosciences Alternatives Monte Rosa Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLTX Stock Alerts